Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Warner Chilcott to Pay $125 Million in False Claims Act Case

Jaclyn Jaeger | October 29, 2015

Warner Chilcott U.S. Sales, a subsidiary of pharmaceutical maker Warner Chilcott, today reached a $125 million settlement with the Department of Justice to resolve criminal and civil liability charges arising from the company’s illegal marketing of seven of its drugs.

Warner Chilcott agreed to plead guilty in the District of Massachusetts to resolve claims that it paid kickbacks to physicians throughout the United States to induce them to prescribe its drugs. Specifically, the plea agreement arises from Warner Chilcott’s illegal marketing of the drugs Actonel, Asacol, Atelvia, Doryx, Enablex, Estrace, and Loestrin.

“Pharmaceutical companies and their employees have a significant responsibility to sell and market drugs in an ethical and legal manner,” said Special Agent in Charge Harold Shaw of the FBI’s Boston Field Office.  “This...

Buy this article for $49, or subscribe to Compliance Week for a month at $149 and get unlimited article access for 30 days.